DRUG GUIDELINE

Alteplase (Intravenous Pulmonary Embolism)
SCOPE (Area): Emergency, ICU
SCOPE (Staff): Medical, Nursing, Pharmacy
Printed versions of this document SHOULD NOT be considered up to date / current


Exclusions

Paediatrics (seek Paediatrician advice) and other wards.


Preamble

See Appendix 1 for full version of this Drug Guideline.


Related Documents

CPG0087 - Investigation And Initial Management Of Patients With Suspected Pulmonary Embolism in the Emergency Department
CPP0012 - Thrombolysis and Endovascular Clot Retrieval (ECR) For Acute Ischaemic Stroke
DRG0038 - Heparin
CPP0222 - User Applied Labelling Of Injectable Medicines, Fluids And Lines
CPP0544 - Intravenous Drug Administration And Classification List
POL0077 - Medication Management
CPP0549 - High Risk Medications
CPP0473 - Alaris Intravenous Infusion System With Guardrails Medication And Fluid Management Software
SOP0001 - Principles Of Clinical Care


References

Alfred Health (2021, September). Management of Pulmonary Embolism Guideline. Alfred Health. Retrieved April 1, 2023.
Barwon Health (2021, August). Alteplase Drug Protocol. Barwon Health. Retrieved April 1, 2023.
Bendigo Health (2015, February). Alteplase (rt-PA) Drug Protocol. Bendigo Health. Retrieved April 1, 2023.
Cabrini Health (2020, December). Alteplase (rt-PA) in Pulmonary Embolism. Cabrini Health. Retrieved April 1, 2023.
MIMS Online. (2023). MIMS Online, Alteplase product information. Retrieved April 2, 2023.
Monash Health (2022, August). Alteplase Adult Medication Profile. Monash Health. Retrieved April 1, 2023
Monash Health (2022, July). Pulmonary Embolus Diagnosis and Management (Adults) Clinical Guideline. Monash Health. Retrieved April 1, 2023.
Northern Health (2020, October). Haematology - Thrombolysis for Massive PE (Adults). Northern Health. Retrieved April 1, 2023.
Northern Health (2022, October). Medication Profile – Alteplase (ADULT). Northern Health. Retrieved April 1, 2023.
Peninsula Health (2021, June). Pulmonary Embolus Thrombolysis – Clinical Practice Guideline. Peninsula Health. Retrieved April 1, 2023.
Peninsula Health (2022, October). Alteplase for Pulmonary Embolism (PE) Adult Drug Administration Guideline. Peninsula Health. Retrieved April 1, 2023.
Rossi, S. (2023, January). Australian Medicines Handbook. Retrieved April 2, 2023.
St Vincent’s Hospital Sydney (2022, October). Alteplase Thrombolysis Pathway for Pulmonary Embolism. St Vincent’s Hospital Sydney. Obtained April 1, 2023 from personal communication.
The Society of Hospital Pharmacists of Australia. (2023). Australian Injectable Drugs Handbook (8th ed.). Retrieved April 2, 2023.
The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (2029). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Retrieved April 7, 2023.
Therapeutic Guidelines Limited. (2023, March). Cardiovascular Guidelines. Retrieved April 2, 2023.
Tran HA et al (2019). New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Retrieved April 7, 2023
UpToDate, Inc. (2023) UpToDate, Drug Interaction section. Retrieved April 2, 2023.


Appendix

Appendix 1 - Alteplase (Intravenous Pulmonary Embolism)



Reg Authority: Medication Safety & Governance Committee (MSGC) Date Effective: 05/12/2023
Review Responsibility: Pharmacist - Rotational Date for Review: 06/12/2026
Alteplase (Intravenous Pulmonary Embolism) - DRG0052 - Version: 3 - (Generated On: 26-04-2025 05:45)